Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive...

Radiance has been selected to Present at the 2025 Biotech Showcase™ Alongside the J.P. Morgan Healthcare Conference BOSTON, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. a biotechnology company developing next generation Antibody Drug Conjugates (“ADCs”) and Bispecific ADCs (“BsADCs), announced that...

Radiance BioPharma sponsoring Investor Cruise Event 2024 BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...